Sjoerd Wadman

LanthioPep BV specializes in vivo stability of therapeutic and diagnostic imaging peptides. Its products include pancyte, lanthi apelin and galanin agonist. The company is headquartered in Groningen, the Netherlands.

Novacta Biosystems Ltd. discovered and developed drugs for treatment of bacterial infections. Its products included lantibiotic/bacteriocin variants, as well as a development candidate for the treatment of C. difficile infection. The company was founded by John Michael Dawson on February 14, 2015 and was headquartered in London, the United Kingdom.

Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany.

Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands.